Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients
et al., Clinical Infectious Diseases,
Retrospective 180,351 patients in Israel, 4,737 treated with paxlovid, showing significantly lower combined severe COVID-19 / mortality with treatment.
risk of severe case or mortality, 46.0% lower, HR 0.54, p < 0.001, treatment 4,737, control 175,614, adjusted per study, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Najjar-Debbiny et al., 6/2/2022, retrospective, Israel, Middle East, peer-reviewed, 8 authors, study period 1 January, 2022 - 28 February, 2022.